Help me understand Takeda logic?

Quote

Anonymous

Guest
I understand that Takeda is going to launch an "exciting new SSRI" soon. Hmmm...launching an exciting new product in a class that has well established, proven generic agents already dominating the market?

Doesn't this sound like an exact repeat of Edarbi? Oh, we have data showing the unique properties of the new SSRI. This one will be different, besides we have talented sales reps at Takeda to drive this product. Didn't Edarbi also claim that?

Where is Edarbi now?

Is anyone else concerned about this?
 




Anonymous said:
I understand that Takeda is going to launch an "exciting new SSRI" soon. Hmmm...launching an exciting new product in a class that has well established, proven generic agents already dominating the market?

Doesn't this sound like an exact repeat of Edarbi? Oh, we have data showing the unique properties of the new SSRI. This one will be different, besides we have talented sales reps at Takeda to drive this product. Didn't Edarbi also claim that?

Where is Edarbi now?

Is anyone else concerned about this?
Click to expand...

Go away Novo troll. I'm sorry you were RIF'd by Takeda
 








Anonymous said:
Go away Novo troll. I'm sorry you were RIF'd by Takeda
Click to expand...

I ask a logical question and this is the response? Typical Takeda hack. Edarbi was launched the exact same way and we had the exact same concerns....and look what happened.

Now they want to do the same thing with the SSRI?

What's the definition of insanity? Doing the same thing over and over and expecting a different result? Or is that the definition of Takeda Marketing Strategy?

Sorry I'm not a troll. Just a concerned individual with a logical question that you obviously can't give a logical answer to, so you spew dumb troll messages. Sorry you have no clue.
 




Anonymous said:
I ask a logical question and this is the response? Typical Takeda hack. Edarbi was launched the exact same way and we had the exact same concerns....and look what happened.

Now they want to do the same thing with the SSRI?

What's the definition of insanity? Doing the same thing over and over and expecting a different result? Or is that the definition of Takeda Marketing Strategy?

Sorry I'm not a troll. Just a concerned individual with a logical question that you obviously can't give a logical answer to, so you spew dumb troll messages. Sorry you have no clue.
Click to expand...

Japanese market is different - much more brand loyalty, in addition western drugs (sometimes already generic in EU or US) are introduced several years later in Japan - may be the genial decision makers at Takeda use Japanese market as the role model...
 




Anonymous said:
Japanese market is different - much more brand loyalty, in addition western drugs (sometimes already generic in EU or US) are introduced several years later in Japan - may be the genial decision makers at Takeda use Japanese market as the role model...
Click to expand...

Good point on the disconnect between Japan and the US, but one still has to wonder that the stench of the Edrbi failure must still be pretty strong? Why would this be any different? kamikaze mentality perhaps?
 




Anonymous said:
I understand that Takeda is going to launch an "exciting new SSRI" soon. Hmmm...launching an exciting new product in a class that has well established, proven generic agents already dominating the market?

Doesn't this sound like an exact repeat of Edarbi? Oh, we have data showing the unique properties of the new SSRI. This one will be different, besides we have talented sales reps at Takeda to drive this product. Didn't Edarbi also claim that?

Where is Edarbi now?

Is anyone else concerned about this?
Click to expand...

This is not a typical SSRI. do some homework, heck just google the drug and find out what it is all about. There are several mechanisms that make it a unique product.
 








Anonymous said:
Edarbi wasn't the typical ARB. Highest binding affinity, only one with chlorthalidone, ect...
Click to expand...

Takes this info for what it's worth. I had just received the Edarbi family this Summer and was really starting to move the drug. I'm pissed that I lost it because "coin" was gonna be very very good. Edarbychlor was out long enough to where we could get some decent activity; launching a new product has it's growing pains and I'm fine with that but let the sales people CARRY the product through so we can get our just rewards.
 
















Anonymous said:
.....like Edarbi......like Rozerem......do I need to continue?
Click to expand...

Unique properties of the new ssri

Rozerem is a novel sleep compound, non addictive, blah blah blah

Edarbi has the highest binding affinity, superiority data

Amitza is a smarter chloride channel activator, which is the new BS our RSD has us pushing..LOL
 




My 2 cent theory: SSRI market is so big you only need a small percent market share to make good money off it. Won't be easy for reps but would bring in revenue for Takeda.

OK, commence trashing me..........wait for it............wait for it.........

(nothing gets posted here without a hostile response)
 




Anonymous said:
My 2 cent theory: SSRI market is so big you only need a small percent market share to make good money off it. Won't be easy for reps but would bring in revenue for Takeda.

OK, commence trashing me..........wait for it............wait for it.........

(nothing gets posted here without a hostile response)
Click to expand...

Not going to trash you....but that was the same theory with brining Edarbi to market
 




Anonymous said:
Not going to trash you....but that was the same theory with brining Edarbi to market
Click to expand...
Hypertension is way different than depression. Patients build a tolerance to SSRI's and cycle through them like crazy. You make it sound like pharma companies can wave a magic wand and have first in class products pop up like fruit trees. We have a ton of products launching right now, many people with Nesina are making the biggest bonuses they have made in 4 years yet you are still hating. Have you ever thought that maybe sales is not the best career choice for you?
 




Anonymous said:
Hypertension is way different than depression. Patients build a tolerance to SSRI's and cycle through them like crazy. You make it sound like pharma companies can wave a magic wand and have first in class products pop up like fruit trees. We have a ton of products launching right now, many people with Nesina are making the biggest bonuses they have made in 4 years yet you are still hating. Have you ever thought that maybe sales is not the best career choice for you?
Click to expand...

Maybe US pharmaceutical development isn't for Takeda?
 




Anonymous said:
Hypertension is way different than depression. Patients build a tolerance to SSRI's and cycle through them like crazy. You make it sound like pharma companies can wave a magic wand and have first in class products pop up like fruit trees. We have a ton of products launching right now, many people with Nesina are making the biggest bonuses they have made in 4 years yet you are still hating. Have you ever thought that maybe sales is not the best career choice for you?
Click to expand...

The goals that Nesina people have are minimal, a monkey could make good bonus with that. Just keeping you sheep busy until the ax falls. Just keep tapping your red pumps, you're not in Kansas any more.
 




The biggest problem I see with Takeda is that it is filled with upper management types who came up riding on the tails of Actos and Prevacid. These morons think they were the reason for the success of those products, when the reverse was true. Blind monkeys could be successful selling Actos. It had one competitor, Lilly was driving most of the sales, and even still GSK held the lead until the FDA had to step in. So now the people who sold one product against one crippled competitor with marginal success wants to tell us how to sell is a tough market with viable generic competition? Sorry, ain't gonna work. Is it any wonder why Rozerem, Edarbi, etc.. tanked?
 








Top Bottom
Back
Quote